Investors waiting for M&A activity in the controversial purified pharma-grade fish oil market got some Tuesday morning, but probably not with the company they were expecting. AstraZeneca (NYSE:AZN) announced the acquisition of third-in-line pharma-grade fish oil company Omthera (Nasdaq:OMTH) for up to $443 million in total consideration. Although the deal offers a significant premium to where Omthera was trading and makes sense as a platform/portfolio addition, it's not exactly a risky high-value deal for AstraZeneca.
To read the full article, please click here:
http://www.investopedia.com/stock-analysis/052813/astrazeneca-looks-fish-oil-round-out-its-cardio-portfolio-azn-omth-amrn.aspx
Home
»
Amarin
»
AstraZeneca
»
Investopedia
»
Omthera
» Investopedia: AstraZeneca Looks To Fish Oil To Round Out Its Cardio Portfolio
Tuesday, May 28, 2013
Related Posts
- Investopedia: Easy To Like Everything About Kubota Except The Price
There's a lot working in Kubota's (OTC:KUBTY) favor these days. The lower value of the yen makes it...Read more
- Investopedia: Waiting For Hormel To Get Cheaper Isn't Getting Any Easier
Once in a while even the best-loved food and beverage companies will sell off on concerns about orga...Read more
- Investopedia: Hain Celestial's Valuation Already Incorporates Strong Expectations
Even as someone who isn't all that interested in the “healthy lifestyle” trends of today, I find it...Read more
- Investopedia: HP Still Looks Cheap, But Execution Issues Are Part Of The Reason Why
There's a big difference between “cheap” and “cheap for a good reason”, and it's not always easy to ...Read more
- Investopedia: Abercrombie & Fitch The Latest To Get Trampled
This is turning out to be a cruel summer for teen retailers, with Abercombie & Fitch (NYSE:ANF) ...Read more
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.